Major global investors continued to accumulate PolTREG shares in 2023, adding another 129,000 shares, and bringing the total to 1.27 million. Investment funds including well-known investors like TFI Allianz Polska – part of the Allianz Group – and Norges Bank Investment Management, collectively hold over 25% of PolTREG’s shares. The trust of these global investors underscores the significant commercial potential of the cell therapies against autoimmune diseases PolTREG S.A. is developing.